Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below 200-Day Moving Average of $7.01

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.01 and traded as low as $4.19. Eagle Pharmaceuticals shares last traded at $4.24, with a volume of 130,155 shares traded.

Eagle Pharmaceuticals Price Performance

The company has a fifty day moving average of $5.43 and a 200-day moving average of $7.01. The firm has a market capitalization of $55.08 million, a PE ratio of 3.59 and a beta of 0.41.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in Eagle Pharmaceuticals by 623.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 5,896 shares in the last quarter. Headlands Technologies LLC raised its holdings in Eagle Pharmaceuticals by 263.4% during the third quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 1,686 shares in the last quarter. DGS Capital Management LLC bought a new position in Eagle Pharmaceuticals during the fourth quarter valued at about $60,000. Aristides Capital LLC bought a new position in Eagle Pharmaceuticals during the fourth quarter valued at about $86,000. Finally, Oxford Asset Management LLP bought a new position in Eagle Pharmaceuticals during the fourth quarter valued at about $101,000. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.